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an investigator-led trialwith limited access to a single anaero-
bic chamber at only 1 center, making it impossible to process
autologous FMT stool anaerobically at each trial site. We be-
lieve, however, that the risk of bias from this is minimal.
Autologous stool samples were processed at room tem-
perature and frozen within minutes of laboratory delivery.
Therefore, there was not sufficient time, nor optimized
growth conditions, for significant proliferation of oxygen-
tolerant organisms, such as Enterobacteriaceae, during pro-
cessing. While the relative proportion of oxygen-tolerant,
potentially pathogenic bacteria was likely to be higher follow-
ing aerobic processing, the overall number of such organisms
would not likely have been increased. Although the autolo-
gous stool may have been devoid of some beneficial organ-
isms due to aerobic processing, this would not have intro-
duced significantly increased numbers of pathogens and thus
should not have significantly reduced the placebo response.
Of course, much of this explanation is supposition based
on best evidence available, and the answer can only be clari-
fiedwith a randomized clinical trial comparing anaerobic and
aerobic donor FMT groups.
It isnotclear thatsteroidspotentiatetheeffectofdonorFMT
becausetherearenohumantrialspoweredtoassessthis.Benech
andcolleagues citedata fromamurinemodel in supportof this
notion.3 Post hoc analyses from 2 previous randomized FMT
studies in humans with ulcerative colitis demonstrated no ef-
fect of steroid therapy on remission.4,5 Paramsothy et al4 re-
ported that 0 of 9 patients in the donor FMT group who en-
tered the trial while taking steroids achieved remission.
Conversely, in the post hoc logistical regression analysis in our
study, oral steroidswere associatedwith a greater reduction in
totalMayoscore followingdonorFMT.Therefore, thedata from
human trials are inconsistent on this question.
It is also unclear whether the length of time receiving ste-
roid therapy prior to enrollment would influence any puta-
tive effect. The patients entering our trial taking steroid
therapy underwent a mandatory steroid taper, which would
have diminished any late steroid effect as steroid therapy
ongoing at week 8 was considered therapeutic failure. In
addition, only aminority of patients entered the study receiv-
ing steroid therapy, and there was no statistical difference
between the number of patients taking steroids in the donor
FMT and autologous FMT groups (8/38 [21%] vs 11/35 [31%];
odds ratio, 0.67 [95% CI, 0.23-1.80]; P = .61). Therefore, any
differences in steroid therapy duration prior to enrollment
are unlikely to have significantly influenced the rate of remis-
sion overall.
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Solutions to ReduceUnnecessary Imaging
To the EditorDrOren and colleagues1 provided suggestions for
curbingunnecessaryandwasteddiagnostic imaging.They im-
pliedthatphysiciansneedmoreeducationaboutorderingtests,
should learn about diagnostic waste, and are often unpre-
pared to handle incidental findings discoveredduring unnec-
essary diagnostic imaging. Such reeducationmay be difficult
andmay have variable results. There is an easierway tomake
a difference.
The authors have ignored a principal and more easily
correctable problem: the cost of defensive medicine. In a
survey of 824 physicians, 93% reported practicing defensive
medicine and “43% reported using imaging technology in
clinically unnecessary circumstances” as a form of “assur-
ance behavior.”2 The authors cited the reduced rate of diag-
nostic imaging in Finland, but that may not be an appropri-
ate comparison given that the Finnish Patient Insurance
Centre handles all claims in the country and that the per-
sonnel involved in treatment are not accused or sued when-
ever patient injury is recognized. This no-guilt principle has
been successful.
Among themost commoncausesof legal complaints in the
United States is delayed or failed diagnosis, including failure
toorder adiagnostic study.Ordering anunnecessary studyof-
ten is forgiven as due diligence.
Reducing reimbursement for certain diagnostic proce-
dures, training radiologists to read lessandgatekeepmore, and
educating physicians on how to handle too much informa-
tion are all good suggestions. However, in the absence of uni-
form legislation thatwillmitigate the fearof adevastating law-
suit, these approaches will be overshadowed by physicians’
self-protective instincts.
Frederick A. Simeone, MD
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TotheEditor Imagingexaminationscarryrisksandarethefourth
largest contributor to patient care debt.1 At the same time, ap-
propriate imagingcanreducebothemergencydepartment (ED)
length of stay and hospitalization rate, the 2 largest contribu-
tors to bills that burden patients.1 In a Viewpoint on reducing
unnecessary diagnostic imaging, Dr Oren and colleagues2 re-
ported a paucity of randomized clinical trials (RCTs) related
to improving ordering appropriateness. We highlight 3 RCTs
related to imaging value.
An RCT by Zafar et al3 evaluated the effects of perfor-
mance feedback reports on high-cost imaging utilization.
Through capture of data during order entry, these reports
compared each ordering physician with their peers. A sig-
nificant reduction in primary care physician ordering of
magnetic resonance imaging of the lumbar spine for low
back pain was found. Performance feedback reports alone
(37% reduction in orders) were more effective than a combi-
nation of clinical decision support alerts and performance
feedback reports (27% reduction) or clinical decision sup-
port alerts alone (no change).
Regarding imaging value, coronary computed tomogra-
phyangiography (CCTA) forchestpainhasbeenstudied inmul-
tiple RCTs. For example, the ROMICAT-II trial4 randomized
1000 ED patients with chest pain and intermediate likeli-
hood of acute coronary syndrome to standard care vs CCTA.
Use of CCTA significantly reduced ED length of stay and in-
creased rateofEDdischarge (47%vs 12%;P < .001).At28days,
havinghadCCTAwas associatedwithmore testing and radia-
tionexposure,butnodifference incost.TheSCOT-HEARTtrial5
randomized4146patientswith stable angina to standard care
with or without CCTA. Follow-up over a median of 4.8 years
revealed a significant decrease in coronary-related death and
nonfatal myocardial infarction with use of CCTA.
As improvements in health care quality, safety, and af-
fordability are soughtby reducing theunnecessaryuseof tests
and treatments, the total cost of care for patients and patient
outcomes also must be considered. Appropriate imaging ex-
aminationsprotect patients frommore costly elementsof care
and translate to reducedmorbidity andmortality and, as such,
are equally important to high-value care.
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To the Editor Dr Oren and colleagues stated that unnecessary
diagnostic imaging isaproblemandthat thedetectionofharm-
less incidentalomas can lead to a cascade of follow-up stud-
ies that increase patient anxiety and risk and costs to the
system.1 However, their proposed solutions are impractical.
The authors suggested that clinicians engage in a shared
decision-makingprocesswithpatients beforeorderingexami-
nationssuchascomputedtomographicscans. Inan idealworld,
this would be helpful, but unfortunately, clinicians are under
pressure tomovepatients inandoutof theofficequickly.There
isno time for a leisurelydiscussionofwhether apatientwould
like to undergo a computed tomographic scan. Moreover, no
insurer is likely to pay for such discussions.
They also suggested reducing the sensitivity or shadow-
ing nontarget organs in imaging studies. This may incur mal-
practice liability if a scanwas done but a possible early cancer
was missed because its location was shadowed.
They further suggested that automated reading (presum-
ably throughartificial intelligencealgorithms)could reduce the
amount of time radiologists need to read scans, thereby free-
ing them to spendmore time acting as gatekeepers. Artificial
intelligence is not ready for clinical use in image interpreta-
tion andmay never be.
The radiology community is aware of the problem of un-
necessary imaging, and efforts are being made on multiple
fronts to address it. The ChoosingWisely initiative2,3 is an at-
tempt to reduce inappropriate and unnecessary testing of all
kinds (not just imaging). As of late 2016, 77 national medical
societies had each created lists of 5 or more such tests. How-
ever, trying to find a specific imaging test among more than
400 recommendations is cumbersome and time consuming
for clinicians.We scrutinized the entireChoosingWiselyweb-
site and selected the 103 imaging tests that at least 1 society
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labeled as inappropriate or often unnecessary4 and organized
them into 11 tables by body area or type of imaging (eg, neuro-
radiology, abdomen/pelvis). These quick and simple-to-use
tables may enable both primary care physicians and special-
ists to substantially reduce unnecessary andwasted imaging.
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In ReplyDr Simeone argues that the litigiousmedicalmilieu in
the United States is a key driver of overutilization of diagnos-
tic imaging compared with a litigation-free environment like
Finland.We agree that defensivemedicinemay contribute to
the rise in the use of diagnostic imaging, including nonindi-
cated testing. However, liability fearmay not explainmost of
theexcessmedical tests.Aneconomicanalysis suggestedthat,
in the no-liabilitymodel of themilitary in which patients can
seek treatment frommedical institutions but are barred from
suingfornegligentcare,healthcarespendingdecreasedbyonly
5%inactive-dutycomparedwithnon–active-dutypatientsand
the clinical outcomes (mortality and readmission rates) were
similar.1Nevertheless, systemicefforts to reduce litigationare
worth exploring, even if a legislative landscape similar to
FinlandisunlikelytohappenintheUnitedStatesanytimesoon.
Dr Johnsonandcolleagues suggest that advanced imaging
can translate into better patient outcomes, using the
ROMICAT-IIandSCOT-HEARTtrialsasexamples.2,3These trials
were not designed to assess the detection of incidentalomas,
amajorproblemwithunnecessary imaging, asdiscussed inour
Viewpoint.4 In the ROMICAT-II trial, the 28-day health care
costs were similar in both groups, yet the number of patients
withanewdiagnosis other thanacute coronary syndromewas
10 points higher in the CCTA group compared with the con-
trol group.Nodatawereprovidedabout thenatureof thenon-
cardiac diagnoses, and the long-term clinical, financial, and
emotional implicationsof suchdiagnosesareunknown.Avalu-
able addition to clinical trials could be long-term follow-up of
incidentallydetectedabnormalities andquantificationof their
individual effect on a patient’s survival and quality of life.
Drs Levin and Rao do not think that preimaging-informed
decision making is practical in the current time-compressed
health care system. We argue that time has to be created for
such discussions, which eventually may save resources and
time as fewer testswould be performed. Such a stepwould be
similar to obtaining informed consent for a patient undergo-
ing any invasive intervention. Subjecting a patient to a non-
urgent imaging test without providing information on its po-
tential long-term consequences does not represent good care
in our opinion. Informed consent and shared decision mak-
ing need to be adapted to current challenges. Levin and Rao
alsomaintain that reducing off-target image sensitivity is not
feasible because of the litigation risk it would create. How-
ever, it may be feasible with proper shared decision making.
For clinical scenarios of noncritically ill patients who do not
have multiorgan systemic conditions, the patient and physi-
cian can decide whether to proceed with a resolution-
adjusted image afterweighing the risks of finding an inciden-
taloma and those ofmissing a clinically important lesion due
to the lower resolution. As for automatic reading of imaging
tests by artificial intelligence rather than radiologists, this is
something that is not just defendable, but also ethically ad-
visable and possibly preferable. In some areas, artificial intel-
ligence reading is being shown to be noninferior to reading of
the same images by radiologists.5
Ohad Oren, MD
Electron Kebebew, MD
John P. A. Ioannidis, MD, DSc
AuthorAffiliations:Division ofHematology andOncology,MayoClinic,
Rochester,Minnesota (Oren); Department of Surgery, Stanford University School
ofMedicine, Stanford, California (Kebebew);Meta-Research Innovation Center
at Stanford (METRICS), Stanford University, Stanford, California (Ioannidis).
Corresponding Author:Ohad Oren, MD, Division of Hematology and Oncology,
Mayo Clinic, 200 First St, Rochester, MN 55901 (ohadoren@gmail.com).
Conflict of Interest Disclosures:None reported.
1. Frakes MD, Gruber J. NBERworking paper series: defensive medicine:
evidence frommilitary immunity: working paper 24846. https://www.nber.org/
papers/w24846.pdf. Published July 2018. AccessedMarch 12, 2019.
2. Hoffmann U, Truong QA, Schoenfeld DA, et al; ROMICAT-II Investigators.
Coronary CT angiography versus standard evaluation in acute chest pain.N Engl
J Med. 2012;367(4):299-308. doi:10.1056/NEJMoa1201161
3. Newby DE, Adamson PD, Berry C, et al; SCOT-HEART Investigators. Coronary
CT angiography and 5-year risk of myocardial infarction.N Engl J Med. 2018;
379(10):924-933. doi:10.1056/NEJMoa1805971
4. Oren O, Kebebew E, Ioannidis JPA. Curbing unnecessary and wasted
diagnostic imaging. JAMA. 2019;321(3):245-246. doi:10.1001/jama.2018.20295
5. Rodriguez-Ruiz A, Lång K, Gubern-Merida A, et al. Stand-alone artificial
intelligence for breast cancer detection in mammography: comparison with 101
radiologists [publishedMarch 5, 2019]. J Natl Cancer Inst. doi:10.1093/jnci/djy222
Meta-analysis of Aspirin for Primary Prevention
of Cardiovascular Events
To the Editor Dr Zheng and Mr Roddick1 reported frequentist
and Bayesian meta-analyses examining the association be-
tweenaspirinuse and cardiovascular events andbleeding risk
in individuals without cardiovascular disease. The investiga-
tors required randomized trials to enroll at least 1000partici-
pants to be eligible for inclusion in the analyses. The basis for
imposing such a study eligibility criteria was not explicitly
justified, but a plausible motivation could be related to the
Letters
jama.com (Reprinted) JAMA June 11, 2019 Volume 321, Number 22 2243
© 2019 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Thomas Jefferson University User  on 06/26/2019
